Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan

SIMPLE SUMMARY: The effects of thiazolidinedione (TZD) on multiple myeloma have not been investigated in humans. The reimbursement database of Taiwan’s National Health Insurance was used to select a propensity score-matched 86,999 pairs of TZD users and non-users who had a new-onset type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autor principal: Tseng, Chin-Hsiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486533/
https://www.ncbi.nlm.nih.gov/pubmed/37686552
http://dx.doi.org/10.3390/cancers15174276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486533/
https://www.ncbi.nlm.nih.gov/pubmed/37686552
http://dx.doi.org/10.3390/cancers15174276

Ejemplares similares